Navigation Links
Æterna Zentaris Receives NASDAQ Notification Related to Minimum Bid Price
Date:1/23/2010

QUEBEC CITY, Jan. 22 /PRNewswire-FirstCall/ - Æterna Zentaris Inc. (NASDAQ: AEZS; TSX: AEZ) (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule"). In accordance with NASDAQ Listing Rule 5810(C)(3)(a), Æterna Zentaris is provided a grace period of 180 calendar days, or until July 20, 2010, to regain compliance with this requirement. The notice has no effect on the listing of Æterna Zentaris' common shares at this time, and its common shares will continue to trade on the NASDAQ under the symbol "AEZS", as well as on the Toronto Stock Exchange under the symbol "AEZ".

Æterna Zentaris can regain compliance with the Rule if the bid price of its common shares closes at US$1.00 or higher for a minimum of ten consecutive business days during the grace period, although NASDAQ may, in its discretion, require the Company to maintain a minimum closing bid price of at least US$1.00 per share for a period in excess of ten consecutive business days before determining that Æterna Zentaris has demonstrated the ability to maintain long-term compliance.

If the Company is unsuccessful in meeting the minimum bid requirement by July 20, 2010, Nasdaq will provide notice to Æterna Zentari
'/>"/>

SOURCE AETERNA ZENTARIS INC.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. AEterna Zentaris completes management team with the appointment of Chief Medical Officer
2. AEterna Zentaris to Present at Upcoming UBS Global Life Sciences Conference in New York
3. AEterna Zentaris Announces Outcome of Managements Strategic Review
4. AEterna Zentaris to Further Develop Three Follow-up Multi-targeted Cytotoxic Candidates to AEZS-112 as Potential Novel Cancer Treatment
5. AEterna Zentaris Reports First Patients Treated with Anti-Cancer Compound AEZS-108 in Phase 2 Trial in Ovarian and Endometrial Cancers
6. AEterna Zentaris to Present at the Upcoming Roth Capital Partners 20th Annual OC Growth Stock Conference in Dana Point, California
7. Aeterna Zentaris to Announce Fourth Quarter and Full-Year 2007 Financial and Operating Results on March 5, 2008
8. AEterna Zentaris Announces the Departure of SVP, Administrative and Legal Affairs
9. AEterna Zentaris and Paladin Labs Announce Sale and Purchase of Miltefosine Rights
10. Aeterna Zentaris Reports Fourth Quarter and Full-Year 2007 Financial and Operating Results
11. Aeterna Zentaris Begins Second Phase 3 Trial of Cetrorelix for Benign Prostatic Hyperplasia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... zFlo Motion , a US leader in ... product from a new partner. STT-Systems has developed ... 15 years, with offerings in the optical-motion capture, 3D scanning, ... (inertial measurement unit), iSen, is opening eyes around the world. ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 Diagenode, ... such as the Bioruptor® and complete solutions for ... for chromatin immunoprecipitation, alleviating the need for manual ... controls needed for ChIP of histones or transcription ...
(Date:1/22/2015)... , a precision medicine software company that has developed a ... genomic, imaging and other biomedical data in research and clinical ... CEO of Aspera, an IBM Company, to its board as ... "We are pleased to welcome Michelle to ...
(Date:12/24/2014)... DALLAS and NEW YORK , ... a biopharmaceutical company advancing patient care in critical areas, announced ... of common stock, and warrants to purchase up to an ... of $4.00 per share and $.01 per warrant.  The warrants ...
Breaking Biology Technology:3D Motion Capture Just Got Easy 2Diagenode Launches Unique Semi-Automated Solution for Chromatin Immunoprecipitation 2GenoSpace Expands Board with Appointment of Michelle Munson 2PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 2PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 3
... 2011 The Plasma Protein Therapeutics Association (PPTA) ... to Orphan Drugs Act ( H.R. 2672 ) and ... drugs and therapies that treat patients with rare diseases by ... who rely on plasma protein therapies are coping with a ...
... NOVATO, Calif., July 28, 2011 BioMarin Pharmaceutical Inc. (Nasdaq: ... GALNS Phase 1/2 extension study (MOR-100) in which patients have ... originally enrolled in the initial Phase 1/2 study of GALNS ... (MOR-100).  In the MOR-100 study, patients were treated at a ...
... fight over deficit reform continues to drag on in Washington, ... across the region to fight to save a critical sector ... a victim of short-sighted cuts. "Proposed cuts to ... to seniors, but would require seniors to pay more for ...
Cached Biology Technology:PPTA Praises Legislation That Protects the Treatment of Rare Diseases 2BioMarin Provides Update on GALNS Phase 1/2 Extension Study (MOR-100) 2BioMarin Provides Update on GALNS Phase 1/2 Extension Study (MOR-100) 3BioMarin Provides Update on GALNS Phase 1/2 Extension Study (MOR-100) 4BioMarin Provides Update on GALNS Phase 1/2 Extension Study (MOR-100) 5BioMarin Provides Update on GALNS Phase 1/2 Extension Study (MOR-100) 6Biotech Group Warns Proposed Medicare Cuts Could Hurt Critical Sector of New England Economy 2
(Date:12/24/2014)... its launch in December 2014, the 1U™ app ... trying to remember their usernames and passwords through replacing the ... To assist people who have struggled to remember usernames and ... and focuses on redefining identity, announced today that it is ...
(Date:12/19/2014)... 2014 Research and Markets ( http://www.researchandmarkets.com/research/86ncd6/micro_market ) has ... America Perimeter Security Systems Market" report to their offering. ... North American perimeter security market is estimated to grow at ... U.S. market holds a larger share in this market, ...
(Date:12/17/2014)... SM announced today its completion of a Good ... current U.S. Food and Drug Administration (FDA) regulations. This ... smart phone application trials utilizing the highest principles for ... determined to improve global healthcare access, quality, and delivery ...
Breaking Biology News(10 mins):1U Offers Best Solution to the Username / Password Dilemma: For FREE! 21U Offers Best Solution to the Username / Password Dilemma: For FREE! 3Micro Market Monitor: North America Perimeter Security Systems Market (Intrusion Detection Sensor, Video Surveillance, Communication/Alarm and Notification, Access Control System) 2Micro Market Monitor: North America Perimeter Security Systems Market (Intrusion Detection Sensor, Video Surveillance, Communication/Alarm and Notification, Access Control System) 3HITLAB Completes GCP Audit for FDA Smart Device & App Compliance 2
... Twenty years after its introduction, gene therapy still holds great ... viruses such as human immunodeficiency syndrome (HIV). But scientists have ... system that is capable of delivering therapeutic payloads to specific ... researchers in the USC Viterbi School of Engineering may be ...
... can safely drive while talking on their cell phones. Vanderbilt ... when it comes to handling two things at once, your ... it that with our incredibly complex and sophisticated brain, with ... a thousand times a second, we still have such a ...
... the National Institutes of Health have developed an experimental ... infected with cytomegalovirus (CMV)—a common virus that can also ... who were infected in early fetal life. , Estimates ... each year at about 40,000, and there is no ...
Cached Biology News:Can engineered immune cells stop AIDS? 2Can engineered immune cells stop AIDS? 3Neural bottleneck found that thwarts multi-tasking 2Neural bottleneck found that thwarts multi-tasking 3Experimental vaccine given during pregnancy reduces stillbirths from common virus 2Experimental vaccine given during pregnancy reduces stillbirths from common virus 3
...
... a-Amylase is an enzyme that catalyzes ... of maltose, maltotriose, and dextrins. The,level ... the human body is of,clinical significance ... including,pancreatitis and diabetes; plant and microbial ...
... Jouan MSC series of Class II ... conditions and certification to the world's ... ensures that the cabinets cannot be ... Natural lighting, low noise and arm ...
... Fluoroskan Ascent FL is ... and luminometric measurement technologies ... list of advanced features ... Luminoskan Ascent. Fluoroskan Ascent ...
Biology Products: